Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 17/20 | 0.60 |
| ▸ | F3 | P13726 | 6/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360265 | 0.90 | F7 (0.65) | F7F3PRSS1F2 | |
| SCHEMBL6792942 | 0.87 | F7 (0.68) | F7F3PRSS1F2PRSS2 | |
| SCHEMBL6793052 | 0.86 | F7 (0.60) | F7F3PRSS1F2PRSS2 | |
| SCHEMBL6793049 | 0.86 | F7 (0.60) | F7F3PRSS1F2PRSS2 | |
| SCHEMBL6795150 | 0.83 | F7 (0.55) | F7F3PRSS1F2 | |
| SCHEMBL8363541 | 0.83 | F7 (0.66) | F7F3PRSS1F2 | |
| SCHEMBL8363138 | 0.83 | F7 (0.68) | F7F3PRSS1F2PRSS2 | |
| SCHEMBL8363577 | 0.83 | F7 (0.73) | F7F3PRSS1F2 | |
| SCHEMBL8360246 | 0.83 | F7 (0.73) | F7F3PRSS1F2 | |
| SCHEMBL8360141 | 0.82 | F7 (0.59) | F7F3PRSS1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, PLG | F7 54/4885F3 20/4885PRSS1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.